Awardee OrganizationUNIVERSITY OF TX MD ANDERSON CAN CTR
Description
Abstract Text
Abstract
Immune-based therapies are generating considerable excitement due to the success of drugs targeting
immune checkpoints. Only small subsets of patients are benefitting from this therapeutic approach, implying
that important molecular modifiers of the tumor microenvironment need to be better understood. Endometrioid-
type endometrial carcinoma (EEC) accounts for approximately 75% of all endometrial carcinomas, the fourth
most common cancer in women in the US. From TCGA data (and validated from our own patient data) we
have identified four transcriptome subtypes of EEC with distinct clinicopathologic characteristics and mutation
spectra. Cluster II consists of younger, obese patients with low grade EEC yet diminished survival. Although
the Cluster II tumors had the lowest overall mutation rate, CTNNB1 exon 3 mutations were very common.
These mutations were associated with activation of the Wnt/-catenin signaling pathway. Thus, exon 3
mutations of CTNNB1 are likely a driver for a subset of more aggressive EEC. We hypothesized for the
parent SPORE proposal that CTNNB1 mutations reprogram the molecular and cellular landscapes leading to
clinically aggressive EEC. In aim 2 of the parent proposal, we will test the hypothesis that CTNNB1 mutation
and Wnt/β-catenin pathway activation result in an immunosuppressive tumor microenvironment that would
contribute to worse survival. For the expansion proposal, we will focus on 2 other molecular pathways,
PTEN and CD73-generated adenosine, that are also important for endometrial carcinoma and may contribute
to localized immune suppression. PTEN loss leading to activation of PI3K/AKT signaling in EEC is common,
occurring in more than 50% of cases. Recent evidence in melanoma suggests that PTEN loss leads to
increased expression of immunosuppressive cytokines, decreased T lymphocyte infiltration into the tumor, and
decreased T lymphocyte-mediated tumor cell death. CD73 is the rate-limiting enzyme in adenosine
biosynthesis. We have recently shown that CD73 helps to maintain cell-cell contacts via filopodia and
membrane zippers that require cortical F-actin polymerization. Loss of CD73 was associated with higher
endometrial cancer grade, advanced endometrial cancer stage, and worse survival. Loss of the cell-cell
contacts leads to defects in the normal epithelial cell barrier function, which may lead to alterations in the tumor
immune microenvironment. The expansion project hypothesis is that PTEN loss and decreased CD73
contribute to endometrial cancer progression by promoting an immunosuppressive tumor microenvironment.
Expansion Specific Aim 1. Determine if PTEN protein loss is associated with an immunosuppressive tumor
microenvironment in EEC. Expansion Specific Aim 2. Determine if loss of CD73 is associated with an
immunosuppressive microenvironment in EEC. For both aims, we will focus on microsatellite-stable EEC and
characterize immune cell infiltrates, PD-L1 expression, and tissue cytokines levels.
Cancer; Clinical Research; Genetics; Uterine Cancer
Sub Projects
No Sub Projects information available for 3P50CA098258-13S1 7324
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3P50CA098258-13S1 7324
Patents
No Patents information available for 3P50CA098258-13S1 7324
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3P50CA098258-13S1 7324
Clinical Studies
No Clinical Studies information available for 3P50CA098258-13S1 7324
News and More
Related News Releases
No news release information available for 3P50CA098258-13S1 7324
History
No Historical information available for 3P50CA098258-13S1 7324
Similar Projects
No Similar Projects information available for 3P50CA098258-13S1 7324